| Bioactivity | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2]. |
| Invitro | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor[1][2]. |
| Name | Nezulcitinib |
| CAS | 2412496-23-0 |
| Formula | C30H37N7O2 |
| Molar Mass | 527.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Theravance's nezulcitinib fails to meet Phase II goals in Covid-19 [2]. Theravance biopharma, inc. Announces top-line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19 |
Nezulcitinib
CAS: 2412496-23-0 F: C30H37N7O2 W: 527.66
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for t
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.